Reactivation of latent tuberculosis infection in TNF-deficient mice

Journal of Immunology

Volumn 171, Issue 6, 2003, Pages 3110-3118

  Botha, Tania ^a   Ryffel, Bernhard ^a,b  

^a CAPE PENINSULA UNIVERSITY OF TECHNOLOGY   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; NITRIC OXIDE SYNTHASE; TUMOR NECROSIS FACTOR;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; BACTERIAL LATENCY; BACTERIAL REACTIVATION; BACTERIAL VIRULENCE; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNE RESPONSE; INFECTION SENSITIVITY; LATENT PERIOD; LIVER; LUNG; LUNG ALVEOLUS MACROPHAGE; MOUSE; MOUSE STRAIN; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE ACTIVATION; TIME SERIES ANALYSIS; TUBERCULOSIS;

EID: 0042834294     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.171.6.3110     Document Type: Article

References (83)

1. Kochi, A. 1991. The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle 72:1.
2. Sudre, P., G. ten Dam, and A. Kochi. 1992. Tuberculosis: a global overview of the situation today. Bull. WHO 70:149.
3. McCune, R. M., and R. Tompsett. 1957. Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. I. The persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy. J. Exp. Med. 104:737.
4. McCune, R. M., R. Tompsett, and W. McDermott. 1957. The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J. Exp. Med. 104:763.
5. McCune, R. M., F. M. Feldmann, H. P. Lambert, and W. McDermott. 1966. Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J. Exp. Med. 123:445.
6. McCune, R. M., F. M. Feldmann, and W. McDermott. 1966. Microbial persistence. II. Characteristics of the sterile state of tubercle bacilli. J. Exp. Med. 123:469.
7. Grosset, J. 1978. The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy. Bull. Int. Union Tuberc. 53:5.
8. Flynn, J. L., C. A. Scanga, K. E. Tanaka, and J. Chan. 1998. Effects of aminoguanidine on latent murine tuberculosis. J. Immunol. 160:1796.
9. Scanga, C. A., V. P. Mohan, H. Joseph, K. Yu, J. Chan, and J. L. Flynn. 1999. Reactivation of latent tuberculosis: variations on the Cornell murine model. Infect. Immun. 67:4531.
10. Botha, T., and B. Ryffel. 2002. Reactivation of latent tuberculosis by an inhibitor of inducible nitric oxide synthase in an aerosol murine model. Immunology 107:350.
11. Orme, I. M. 1988. A mouse model of the recrudescence of latent tuberculosis in the elderly. Am. Rev. Respir. Dis. 137:716.
12. Brown, D. H., B. A. Miles, and B. S. Zwilling. 1995. Growth of Mycobacterium tuberculosis in BCG-resistant and -susceptible mice: establishment of latency and reactivation. Infect. Immun. 63:2243.
13. Phyu, S., T. Mustafa, T. Hofstad, R. Nilsen, R. Fosse, and G. Bjune. 1998. A mouse model for latent tuberculosis. Scand. J. Infect. Dis. 30:59.
14. Mustafa, T., S. Phyu, R. Nilsen, R. Jonsson, and G. Bjune. 1999. A mouse model for slowly progressive primary tuberculosis. Scand. J. Immunol. 50:127.
15. Orme, I. M., and F. M. Collins. 1984. Efficacy of Mycobacterium bovis BCG vaccination in mice undergoing prior pulmonary infection with atypical mycobacteria. Infect. Immun. 44:28.
16. Orme, I. M., E. S. Miller, A. D. Roberts, S. K. Furney, J. P. Griffin, K. M. Dobos, D. Chi, B. Rivoire, and P. J. Brennan. 1992. T lymphocytes mediating protection and cellular cytolysis during the course of Mycobacterium tuberculosis infection: evidence for different kinetics and recognition of a wide spectrum of protein antigens. J. Immunol. 148:189.
17. Flynn, J. L., M. M. Goldstein, K. J. Triebold, B. Koller, and B. R. Bloom. 1992. Major histocompatibility complex class 1-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc. Natl. Acad. Sci. USA 89:12013.
18. Flory, C. M., R. D. Hubbard, and F. M. Collins. 1992. Effects of in vivo T lymphocyte subset depletion on mycobacterial infections in mice. J. Leukocyte Biol. 51:225.
19. Chan, J., and S. H. E. Kaufmann. 1994. Immune mechanisms of protection. In Tuberculosis: Pathogenesis, Protection, and Control. B. R. Bloom, ed. ASM Press, Washington, D.C., p. 389.
20. Cooper, A. M., D. K. Dalton, T. A. Stewart, J. P. Griffin, D. G. Russell, and I. M. Orme. 1993. Disseminated tuberculosis in interferon γ gene-disrupted mice. J. Exp. Med. 178:2243.
21. Flynn, J. L., J. Chan, K. J. Triebold, D. K. Dalton, T. A. Stewart, and B. R. Bloom. 1993. An essential role for interferon γ in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178:2249.
22. Flynn, J. L., M. M. Goldstein, J. Chan, K. J. Triebold, K. Pfeffer, C. J. Lowenstein, R. Schreiber, T. W. Mak, and B. R. Bloom. 1995. Tumor necrosis factor-α is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2:561.
23. Cooper, A. M., J. Magram, J. Ferrante, and I. M. Orme. 1997. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with mycobacterium tuberculosis. J. Exp. Med. 186:39.
24. Denis, M. 1991. Interferon-γ-treated murine macrophages inhibit growth of tubercle bacilli via the generation of reactive nitrogen intermediates. Cell. Immunol. 132:150.
25. Flesch, I. E., and S. H. Kaufmann. 1991. Mechanisms involved in mycobacterial growth inhibition by γ interferon-activated bone marrow macrophages: role of reactive nitrogen intermediates. Infect. Immun. 59:3213.
26. Chan, J., Y. Xing, R. S. Magliozzo, and B. R. Bloom. 1992. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J. Exp. Med. 175:1111.
27. Chan, J., K. Tanaka, D. Carroll, J. Flynn, and B. R. Bloom. 1995. Effects of nitric oxide synthase inhibitors on murine infection with Mycobacterium tuberculosis. Infect. Immun. 63:736.
28. MacMicking, J. D., R. J. North, R. LaCourse, J. S. Mudgett, S. K. Shah, and C. F. Nathan. 1997. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc. Natl. Acad. Sci. USA 94:5243.
29. Kindler, V., A. P. Sappino, G. E. Grau, P. F. Piguet, and P. Vassalli. 1989. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 56:731.
30. Bean, A. G., D. R. Roach, H. Briscoe, M. P. France, H. Korner, J. D. Sedgwick, and W. J. Britton. 1999. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J. Immunol. 162:3504.
31. Jacobs, M., M. W. Marino, N. Brown, B. Abel, L. G. Bekker, V. J. Quesniaux, L. Fick, and B. Ryffel. 2000. Correction of defective host response to Mycobacterium bovis BCG infection in TNF-deficient mice by bone marrow transplantation. Lab. Invest. 80:901.
32. Flesch, I. E., J. H. Hess, I. P. Oswald, and S. H. Kaufmann. 1994. Growth inhibition of Mycobacterium bovis by IFN-γ stimulated macrophages: regulation by endogenous tumor necrosis factor-α and by IL-10. Int. Immunol. 6:693.
33. Ding, A. H., C. F. Nathan, and D. J. Stuehr. 1988. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production. J. Immunol. 141:2407.
34. Garcia, I., R. Guler, D. Vesin, M. L. Olleros, P. Vassalli, Y. Chvatchko, M. Jacobs, and B. Ryffel. 2000. Lethal Mycobacterium bovis bacillus Calmette Guérin infection in nitric oxide synthase 2-deficient mice: cell-mediated immunity requires nitric oxide synthase 2. Lab Invest. 80:1385.
35. 3 metabolites and tumour necrosis factor in the pathogenesis of tuberculosis. Immunology 62:229.
36. Beutler, B., and A. Cerami. 1988. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu. Rev. Biochem. 57:505.
37. Rook, G. A. 1990. The role of activated macrophages in protection and immunopathology in tuberculosis. Res. Microbiol. 141:253.
38. Tracey, K. J., and A. Cerami. 1992. Tumor necrosis factor in the malnutrition (cachexia) of infection and cancer. Am. J. Trop. Med. Hyg. 47:2.
39. Marino, M. W., A. Dunn, D. Grail, M. Inglese, Y. Noguchi, E. Richards, A. Jungbluth, H. Wada, M. Moore, B. Williamson, et al. 1997. Characterization of tumor necrosis factor-deficient mice. Proc. Natl. Acad. Sci. USA 94:8093.
40. Abel, B., N. Thieblemont, V. J. Quesniaux, N. Brown, J. Mpagi, K. Miyake, F. Bihl, and B. Ryffel. 2002. Toll-like receptor 4 expression is required to control chronic Mycobacterium tuberculosis infection in mice. J. Immunol. 169:3155.
41. Green, S. J., R. M. Crawford, J. T. Hockmeyer, M. S. Meltzer, and C. A. Nacy. 1990. Leishmania major amastigotes initiate the L-arginine-dependent killing mechanism in IFN-γ-stimulated macrophages by induction of tumor necrosis factor-α. J. Immunol. 145:4290.
42. Jacobs, M., N. Brown, N. Allie, K. Chetty, and B. Ryffel. 2000. Tumor necrosis factor receptor 2 plays a minor role for mycobacterial immunity. Pathobiology 68:68.
43. Roach, D. R., A. G. Bean, C. Demangel, M. P. France, H. Briscoe, and W. J. Britton. 2002. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J. Immunol. 168:4620.
44. Roach, D. R., H. Briscoe, B. Saunders, M. P. France, S. Riminton, and W. J. Britton. 2001. Secreted lymphotoxin-α is essential for the control of an intracellular bacterial infection. J. Exp. Med. 193:239.
45. Hornung, F., G. Scala, and M. J. Lenardo. 2000. TNF-α-induced secretion of C-C chemokines modulates C-C chemokine receptor 5 expression on peripheral blood lymphocytes. J. Immunol. 164:6180.
46. Bekker, L. G., A. L. Moreira, A. Bergtold, S. Freeman, B. Ryffel, and G. Kaplan. 2000. Immunopathologic effects of tumor necrosis factor α in murine mycobacterial infection are dose dependent. Infect. Immun. 68:6954.
47. Kaufmann, S. H., and C. H. Ladel. 1994. Role of T cell subsets in immunity against intracellular bacteria: experimental infections of knock-out mice with Listeria monocytogenes and Mycobacterium bovis BCG. Immunobiology 191:509.
48. Gordon, S., S. Keshav, and M. Stein. 1994. BCG-induced granuloma formation in murine tissues. Immunobiology 191:369.
49. Andersen, P. 1997. Host responses and antigens involved in protective immunity to Mycobacterium tuberculosis. Scand. J. Immunol. 45:115.
50. Emile, J. F., N. Patey, F. Altare, S. Lamhamedi, E. Jouanguy, F. Boman, J. Quillard, M. Lecomte-Houcke, O. Verola, J. F. Mousnier, et al. 1997. Correlation of granuloma structure with clinical outcome defines two types of idiopathic disseminated BCG infection. J. Pathol. 181:25.
51. Scanga, C. A., V. P. Mohan, K. Tanaka, D. Alland, J. L. Flynn, and J. Chan. 2001 The inducible nitric oxide synthase locus confers protection against aerogenic challenge of both clinical and laboratory strains of Mycobacterium tuberculosis in mice. Infect. Immun. 69:7711.
52. Choi, H. S., P. R. Rai, H. W. Chu, C. Cool, and E. D. Chan. 2002. Analysis of nitric oxide synthase and nitrotyrosine expression in human pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 166:178.
53. Fang, F. C., and A. Vazquez-Torres. 2002. Nitric oxide production by human macrophages: there's NO doubt about it. Am. J. Physiol. 282:L941.
54. Chan, E. D., J. Chan, and N. W. Schluger. 2001. What is the role of nitric oxide in murine and human host defense against tuberculosis? Current knowledge. Am. J. Respir. Cell Mol. Biol. 25:606.
55. Nicholson, S., G. Bonecini-Almeida Mda, J. R. Lapa e Silva, C. Nathan, Q. W. Xie, R. Mumford, J. R. Weidner, J. Calaycay, J. Geng, N. Boechat, et al. 1996. Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis. J. Exp. Med. 183:2293.
56. Kuo, H. P., C. H. Wang, K. S. Huang, H. C. Lin, C. T. Yu, C. Y. Liu, and L. C. Lu. 2000. Nitric oxide modulates interleukin-1β and tumor necrosis factor-α synthesis by alveolar macrophages in pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 161:192.
57. Amiri, P., R. M. Locksley, T. G. Parslow, M. Sadick, E. Rector, D. Ritter, and J. H. McKerrow. 1992. Tumour necrosis factor a restores granulomas and induces parasite egg-laying in schistosome-infected SCID mice. Nature 356:604.
58. North, R. J., and A. A. Izzo. 1993. Granuloma formation in severe combined immunodeficient (SCID) mice in response to progressive BCG infection. Tendency not to form granulomas in the lung is associated with faster bacterial growth in this organ. Am. J. Pathol. 142:1959.
59. Huffnagle, G. B., G. H. Chen, J. L. Curtis, R. A. McDonald, R. M. Strieter, and G. B. Toews. 1995. Down-regulation of the afferent phase of T cell-mediated pulmonary inflammation and immunity by a high melanin-producing strain of Cryptococcus neoformans. J. Immunol. 155:3507.
60. + T cells during Mycobacterium tuberculosis infection. J. Immunol. 167:6991.
61. Baggiolini, M. 1998. Chemokines and leukocyte traffic. Nature 392:565.
62. Zlotnik, A., and O. Yoshie. 2000. Chemokines: a new classification system and their role in immunity. Immunity 12:121.
63. Orme, I. M., and A. M. Cooper. 1999. Cytokine/chemokine cascades in immunity to tuberculosis. Immunol. Today 20:307.
64. Rhoades, E. R., A. M. Cooper, and I. M. Orme. 1995. Chemokine response in mice infected with Mycobacterium tuberculosis. Infect. Immun. 63:3871.
65. Sadek, M. I., E. Sada, Z. Toossi, S. K. Schwander, and E. A. Rich. 1998. Chemokines induced by infection of mononuclear phagocytes with mycobacteria and present in lung alveoli during active pulmonary tuberculosis. Am. J. Respir. Cell Mol. Biol. 19:513.
66. Lin, Y., J. Gong, M. Zhang, W. Xue, and P. F. Barnes. 1998. Production of monocyte chemoattractant protein 1 in tuberculosis patients. Infect. Immun. 66:2319.
67. Kurashima, K., N. Mukaida, M. Fujimara, M. Yasui, Y. Nakazumi, T. Matsuda, and K. Matsushima. 1997. Elevated chemokine levels in bronchoalveolar lavage fluid of tuberculosis patients. Respir. Crit. Care Med. 155:1474.
68. Peters, W., and J. D. Ernst. 2003. Mechanisms of cell recruitment in the immune response to Mycobacterium tuberculosis. Microbes Infect. 5:151.
69. Lu, B., B. J. Rutledge, L. Gu, J. Fiorillo, N. W. Lukacs, S. L. Kunkel, R. North, C. Gerard, and B. J. Rollins. 1998. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J. Exp. Med. 187:601.
70. Peters, W., H. M. Scott, H. F. Chambers, J. L. Flynn, I. F. Charo, and J. D. Ernst. 2001. Chemokine receptor 2 serves an early and essential role in resistance to Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 98:7958.
71. Keane, J., S. Gershon, R. P. Wise, E. Mirabile-Levens, J. Kasznica, W. D. Schwieterman, J. N. Siegel, and M. M. Braun. 2001. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N. Engl. J. Med. 345:1098.
72. Nunez Martinez, O., C. Ripoll Noiseux, J. A. Carneros Martin, V. Gonzalez Lara, and H. G. Gregorio Maranon. 2001. Reactivation tuberculosis in a patient with anti-TNF-α treatment. Am. J. Gastroenterol. 96:1665.
73. Sieper, J., and J. Braun. 2001. New treatment options in ankylosing spondylitis: a role for anti-TNFα therapy. Ann. Rheum. Dis. 60(Suppl. 3):iii58.
74. Keating, G. M., and C. M. Perry. 2002. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. Biodrugs 16:111.
75. Braun, J., J. Brandt, J. Listing, A. Zink, R. Alten, W. Golder, E. Gronmica-Ihle, H. Kellner, A. Krause, M. Schneider, et al. 2002. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359:1187.
76. Criscione, L. G., and E. W. St Clair. 2002. Tumor necrosis factor-α antagonists for the treatment of rheumatic diseases. Curr. Opin. Rheumatol. 14:204.
77. Fleischmann, R., I. Iqbal, P. Nandeshwar, and A. Quiceno. 2002. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept. Drug Safety 25:173.
78. Roth, S., E. Delmont, P. Heudier, R. Kaphan, E. Cua, J. Castela, J. M. Verdier, R. M. Chichmanian, and J. G. Fuzibet. 2002. Anticorps anti-TNFα (infliximab) et tuberculose: a propos de trois caz. Rev. Med. Intern. 23:312.
79. Mayordomo, L., J. L. Marenco, J. Gomez-Mateos, and E. Rejon. 2002. Pulmonary miliary tuberculosis in a patient with anti-TNF-α treatment. Scand. J. Rheumatol. 31:44.
80. Shanahan, J. C., and W. St Clair. 2002. Tumor necrosis factor-α blockade: a novel therapy for rheumatic disease. Clin. Immunol. 103:231.
81. Van Den Bosch, F., E. Kruithof, D. Baeten, A. Herssens, F. de Keyser, H. Mielants, and E. M. Veys. 2002. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum. 46:755.
82. Vonkeman, H. E., P. D. van der Valk, L. Mulder, and M. A. van de Laar. 2002. Fatale miliaire tuberculose tijdens behandeling met infliximab. Ned. Tijdschr. Geneeskd. 146:1196.
83. Weisman, M. H. 2002. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. J. Rheumatol. 65(Suppl.):33.